Medical Oncologist
Medicines
Two years of abemaciclib after surgery: why that duration
After surgery for high-risk hormone receptor positive, HER2-negative breast cancer, abemaciclib is taken for two years with hormone therapy. That length comes from the trial that proved its benefit, and the reduction in recurrence has lasted beyond the tablets stopping. This page explains, in general terms, who it suits and what the two years involve.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed September 2026, next review due September 2027
On this page
- Why is abemaciclib given for two years after surgery?
- What makes a cancer high enough risk for abemaciclib
- What the treatment period usually looks like
- The vocabulary, in plain language
- Honest realities about two years of abemaciclib
- What if you cannot finish the two years?
- Life after abemaciclib finishes
- What people assume about the two-year course
- Common questions about abemaciclib after surgery
The short answer
Why is abemaciclib given for two years after surgery?
After surgery for early hormone receptor positive, HER2-negative breast cancer, abemaciclib is taken for two years alongside hormone therapy by people whose cancer carries a high risk of coming back. High risk usually means the cancer had spread to several lymph nodes in the armpit, or had spread to fewer nodes but was large or fast-growing, as judged by its grade. The two-year duration comes directly from the large monarchE trial, which tested exactly that length of treatment. Researchers chose two years as a balance: long enough to act on microscopic cancer cells during the period when the risk of early recurrence is highest, but short enough that most people could stay on treatment and cope with the side effects. The trial showed fewer recurrences, including fewer cancers returning in distant parts of the body, and that benefit has continued to widen during longer follow-up after the tablets stopped. There is no strong evidence that taking abemaciclib for longer than two years adds benefit in this setting, and it has not been tested for shorter periods. Hormone therapy continues after the two years, usually for five years or more in total. It is important to understand that abemaciclib reduces the risk of recurrence rather than removing it, and that the decision to use it depends on your individual risk, your health and how well you tolerate it.
The duration was tested, not guessed
Two years is the period studied in the trial that led to approval, so it is the duration with evidence behind it.
The benefit continues after stopping
Follow-up after the tablets finished has shown the gap in recurrence rates staying and growing, not shrinking.
Hormone therapy carries on
When abemaciclib stops, your hormone tablets or injections continue as planned.
This page gives general information only. Your oncologist will explain whether abemaciclib suits your situation and for how long.Who it is for
What makes a cancer high enough risk for abemaciclib
The trial included people with features linked to a higher chance of the cancer returning.
Several affected lymph nodes
Cancer found in many lymph nodes in the armpit is one of the strongest signs of higher risk.
Fewer nodes plus other features
Cancer in fewer nodes, together with a large tumour or a high grade, also counted as high risk.
The exact criteria your team uses may vary slightly by guideline.Hormone receptor positive
The cancer must be oestrogen or progesterone receptor positive, because abemaciclib is given with hormone therapy.
HER2-negative
HER2-positive cancers are treated with HER2-targeted medicines instead.
Usually not used when
- Lymph nodes were free of cancer
- You are pregnant or planning pregnancy
- Serious liver problems are present
Across the years
What the treatment period usually looks like
Period
What usually happens
Before starting
Surgery, chemotherapy and radiotherapy as needed, then blood tests
First months
Frequent tests, managing loose motions, possible dose changes
Rest of year one
Side effects usually steadier, visits less frequent
Year two
Continue tablets and hormone therapy, regular reviews
After two years
Abemaciclib stops; hormone therapy and follow-up continue
Words you will hear
The vocabulary, in plain language
- Adjuvant treatment
- Treatment given after surgery to lower the chance of the cancer coming back.
- monarchE
- The large international trial that tested two years of abemaciclib after surgery.
- Invasive disease-free survival
- Time without the cancer returning or a new invasive cancer developing.
- Distant recurrence
- Cancer coming back in other parts of the body, such as bones, liver or lungs.
- Grade
- How abnormal and fast-growing cancer cells look under a microscope.
- Micrometastases
- Tiny groups of cancer cells too small to see on scans.
Talk to our team
Have a question about your situation?
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Being straight with you
Honest realities about two years of abemaciclib
Two years is a long time to live with daily tablets and side effects. It helps to go in with clear expectations.
It lowers risk, it does not remove it
Most people in the trial did well with or without abemaciclib, and some still had a recurrence despite taking it.
Not everyone completes the full course
Some people stop early because of side effects. Dose reductions often help people keep going.
Long-term survival data is still maturing
The recurrence benefit is well established. Ask your oncologist about the latest overall survival results.
What this page cannot tell you
It cannot calculate your personal risk or benefit. Your oncologist can do that using your pathology report.
If plans change
What if you cannot finish the two years?
Stopping early is a worry for many people. It helps to know how teams usually approach it.
Try adjustments first
Pauses, lower doses and supportive medicines are usually tried before stopping, because many side effects improve with these changes.
Stopping is sometimes right
Serious side effects such as lung inflammation or blood clots may mean abemaciclib should stop for good. Your safety comes first.
Hormone therapy still matters most
The hormone medicine is the foundation of treatment. Continuing it well protects much of the benefit even if abemaciclib stops.
Talk before stopping yourself
If you are struggling, tell your team rather than quietly stopping. There are often options you may not know about.
After the two years
Life after abemaciclib finishes
Finishing abemaciclib is a milestone, though treatment and follow-up continue.
Side effects fade
Loose motions and blood count changes usually settle within weeks of stopping the tablets.
Follow-up continues
Regular examinations, yearly mammograms and hormone therapy checks carry on, usually for many years.
Report new symptoms
Persistent bone pain, a new lump, breathlessness or ongoing weight loss should be checked promptly.
Commonly believed
What people assume about the two-year course
Taking it for longer would be even better.
Longer use after surgery has not been shown to add benefit.
The benefit disappears when the tablets stop.
Follow-up has shown the benefit lasting beyond the two years.
If I need a lower dose, I lose the benefit.
Trial analyses suggest reduced doses still appear to help.
Everyone with breast cancer should take it.
It is for selected high-risk, hormone-positive, HER2-negative cancers.
Questions we are asked
Common questions about abemaciclib after surgery
When does abemaciclib start after surgery?
Usually after surgery and any chemotherapy and radiotherapy are finished, and once you have recovered. It is typically started alongside or soon after your hormone therapy begins. Your oncologist will choose the timing that suits your treatment plan and recovery.
Is two years counted from my first tablet?
Generally, yes. The two years is counted from when you start abemaciclib. Short pauses for side effects do not usually mean the course is extended, but your oncologist will guide you if there has been a long interruption.
What if my cancer did not involve lymph nodes?
The trial that led to approval only included people whose cancer had spread to lymph nodes. For node-negative cancers, abemaciclib is not usually recommended after surgery. Another CDK4/6 inhibitor, ribociclib, has been studied in a broader group, and your oncologist can explain the difference.
Do I still need hormone therapy?
Yes. Abemaciclib is added to hormone therapy, not used instead of it. Hormone therapy continues after the two years, commonly for five years in total and sometimes longer, depending on your risk and how you are coping.
Will I need chemotherapy as well?
Many people with high-risk cancers have chemotherapy before or after surgery, before starting abemaciclib. Abemaciclib does not replace chemotherapy when it is recommended. Your oncologist will explain the full sequence of treatment for you.
Can men take abemaciclib after surgery?
Men with high-risk hormone receptor positive, HER2-negative breast cancer were included in the trial, though in small numbers. Oncologists may recommend it for men using the same principles, alongside suitable hormone therapy.
What if the cancer comes back while I am on it?
This is uncommon but possible. Your team would carry out tests to confirm it and then plan different treatment, which may include other targeted medicines, hormone treatments or chemotherapy, depending on the situation.
Is two years of abemaciclib worth the side effects?
That depends on your risk of recurrence, your health and your own values. For people at higher risk, the reduction in recurrence is meaningful. Ask your oncologist to explain your likely benefit in plain terms before deciding.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Where to find us
Our centres in and around Hyderabad
Addressed by landmark, because that is how this city navigates. Each centre also names the areas it serves, so you can place it without a map. Consultation and day-care Chemotherapy run at every one of them.
Warangal
Vizag
Talk to our team
Speak to a breast cancer specialist
Call the helpline or leave your details, and someone will help you arrange a consultation at the CION centre nearest you. One helpline serves every CION centre.
Call 1800 202 8726
Helpline open 24/7
Sources
- Journal of Clinical Oncology — Abemaciclib combined with endocrine therapy for the adjuvant treatment of high-risk early breast cancer (monarchE)
- National Cancer Institute — Abemaciclib
- European Medicines Agency — Verzenios: product information
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.